Intra-Cellular Therapies’ pipeline is focused on three platforms: ITI-007 including lumateperone, a phosphodiesterase 1 (PDE1) inhibitor platform and our discovery platform which includes ITI-333.
The safety and efficacy of these investigational agents have not been established.
